-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
-
-
-
-
-
-
Alnylam presents vutrisiran and zilebesiran data at ESC 2026
-
-
-
-
-
-
-
Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data
-
-
-
-
-
-
-
Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $447 at Bernstein SocGen Group
-
-
-
-
-
-
-
BofA on Alnylam (ALNY): 'AI-enabled diagnostics will help increase diagnosis rates'
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $450 at RBC Capital
-
480,485 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


